Avanos Medical (AVNS) has recently attracted attention after a period of strong stock performance, with the share price up 87% over the past 3 months and 124% year to date.
See our latest analysis for Avanos Medical.
The recent rally appears concentrated in the past quarter, with a 90 day share price return of 86.79% and a 1 year total shareholder return of 93.88%. This contrasts with a 5 year total shareholder return that is down 37.38%, suggesting renewed momentum after a weaker longer term experience.
If you are looking beyond Avanos Medical and want to spot other potential movers in healthcare technology, this could be a useful moment to scan for 39 healthcare AI stocks
With Avanos shares rebounding after a weaker multi year stretch and the company still reporting a loss on US$715.9 million of revenue, the key question is whether the recent surge leaves upside on the table or if markets are already pricing in future growth.
Preferred Price-to-Sales of 1.6x: Is it justified?
On recent data, Avanos Medical trades on a P/S of 1.6x, which sits below both industry peers and the wider US Medical Equipment sector even after the sharp share price move.
The P/S ratio compares the company’s market value to its revenue. For every $1 of annual sales, investors are currently paying $1.60 for Avanos. For a medical technology company with US$715.9 million of revenue and a reported net loss of US$74.4 million, sales-based metrics are often watched closely when earnings are negative.
According to Simply Wall St’s checks, Avanos is described as good value against the US Medical Equipment industry average P/S of 2.7x and a peer average of 2.3x. However, it is labelled expensive versus an estimated fair P/S of 1.1x that the SWS fair ratio model suggests the market could ultimately move towards. That mix of cheaper than peers but richer than the modelled fair level points to a market that is willing to pay a premium to the regression-based fair ratio while still assigning a lower tag than many competitors.
Result: Price-to-sales of 1.6x (ABOUT RIGHT)
Explore the SWS fair ratio for Avanos Medical
However, investors still face risks if Avanos remains loss making on US$715.9 million of revenue, or if its lower P/S multiple starts to converge toward peers.
Find out about the key risks to this Avanos Medical narrative.
Next Steps
If the recent share price strength leaves you unsure, this is the moment to move quickly, assess the numbers yourself, and weigh the 2 important warning signs.
Looking for more investment ideas?
If Avanos has sharpened your focus on opportunities, do not stop here. Use targeted stock lists to spot other ideas that could fit your approach.
- Spot potential value opportunities early and scan a focused list of 46 high quality undervalued stocks before other investors catch on.
- Prioritise resilience and check companies with stronger finances through the solid balance sheet and fundamentals stocks screener (46 results) so weak balance sheets do not catch you off guard.
- Hunt for underfollowed ideas by reviewing the screener containing 21 high quality undiscovered gems that may not yet be on many investors’ radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com